# Multi-Modal Resistance Prediction for Ovarian Cancer
## Collaboration Opportunity: CA-125 Kinetics Validation Study

**CrisPRO.ai Research Initiative**  
Contact: Fahad Kiani | Fahad@CrisPRO.ai | linkedin.com/in/fjkiani

---

## The Clinical Problem

**Current standard:** Resistance detection relies on imaging (CT/PET) ‚Üí **9-12 weeks on ineffective therapy** before switching treatment.

**Impact:** Delayed switches reduce PFS, increase toxicity burden, limit salvage options.

**Our hypothesis:** CA-125 kinetics can detect resistance **3-6 weeks earlier** ‚Üí faster clinical decisions, improved outcomes.

---

## What We've Built

### ‚úÖ Baseline Stratification (Validated - Tier 3)
- **MAPK pathway mutations** (KRAS/NRAS/BRAF/NF1) stratify platinum resistance risk
- **TCGA-OV validation** (n=469): RR=1.97 (95% CI: 1.01-3.84), p=0.05, AUROC=0.60
- **Clinical utility:** 60% resistance rate (MAPK+) vs 30% (MAPK-WT) ‚Üí informs monitoring intensity

### ‚è≥ CA-125 Kinetics (Needs Validation - **YOUR HELP**)
- **Velocity-based analysis** (not just GCIG doubling)
- **Hypothesis:** Deceleration/plateau patterns detect resistance 3-6 weeks before imaging
- **Status:** Implemented and production-ready, needs retrospective cohort validation

### üéØ Multi-Signal Convergence
- **Integration:** Baseline genetics + CA-125 kinetics = higher confidence predictions
- **Hypothesis:** Combined AUROC ‚â•0.70 (vs 0.60 baseline alone)
- **System:** Ring-1 validated API, operational, patient-ready

---

## What We Need: Your Data

**Minimum requirements (n‚â•50 patients):**
- ‚úÖ Serial CA-125 measurements (baseline ‚Üí progression, ideally q3weeks)
- ‚úÖ Treatment start date (platinum-based chemotherapy)
- ‚úÖ Imaging progression date (RECIST or clinical)

**Optional (enhances validation):**
- Baseline genomics (MAPK/BRCA/TP53)
- Treatment regimen details
- Survival data (PFS, OS)

**Format:** De-identified CSV/Excel  
**IRB:** Retrospective, de-identified (expedited review, we provide template
